AU2014296212B2 - Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate - Google Patents

Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Download PDF

Info

Publication number
AU2014296212B2
AU2014296212B2 AU2014296212A AU2014296212A AU2014296212B2 AU 2014296212 B2 AU2014296212 B2 AU 2014296212B2 AU 2014296212 A AU2014296212 A AU 2014296212A AU 2014296212 A AU2014296212 A AU 2014296212A AU 2014296212 B2 AU2014296212 B2 AU 2014296212B2
Authority
AU
Australia
Prior art keywords
protein
family
domain
receptor
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014296212A
Other languages
English (en)
Other versions
AU2014296212A1 (en
Inventor
Rashida A. Karmali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tactical Therapeutics Inc
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of AU2014296212A1 publication Critical patent/AU2014296212A1/en
Application granted granted Critical
Publication of AU2014296212B2 publication Critical patent/AU2014296212B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2014296212A 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate Active AU2014296212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (2)

Publication Number Publication Date
AU2014296212A1 AU2014296212A1 (en) 2016-02-25
AU2014296212B2 true AU2014296212B2 (en) 2020-10-22

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014296212A Active AU2014296212B2 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Country Status (9)

Country Link
US (1) US10378059B2 (enExample)
EP (1) EP3027776B1 (enExample)
JP (1) JP6913459B2 (enExample)
KR (1) KR102389934B1 (enExample)
CN (1) CN105531380B (enExample)
AU (1) AU2014296212B2 (enExample)
CA (1) CA2919690C (enExample)
IL (1) IL243894B (enExample)
WO (1) WO2015017545A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202760A1 (en) * 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227205C (en) * 1995-07-21 2007-05-01 Constantia Gruppe Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
SI1504126T1 (sl) 2002-05-03 2014-08-29 Duke University Office Of Science And Technology Postopek regulacije izraĹľanja genov
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
AU2008232732A1 (en) 2007-03-28 2008-10-09 Medarex, Inc. Methods of gene amplification and expression
JP2011515088A (ja) * 2008-03-22 2011-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 増殖因子シグナル伝達経路レギュレーション状態を評価するための方法及び遺伝子発現サイン
KR101597338B1 (ko) * 2009-09-04 2016-02-24 탁티칼 떼라페우틱스 인크. 5-아미노 또는 치환된 아미노 1,2,3-트리아졸 화합물 및 이의 오로트산염 제형들의 신규한 조성물들 및 이의 제조방법
JP6355555B2 (ja) * 2011-04-01 2018-07-11 キアゲン Ｗｎｔ／ｂ−カテニンシグナル伝達経路に関する遺伝子発現シグネチャーおよびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120202760A1 (en) * 2009-09-04 2012-08-09 Rashida A. Karmali Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anonymous, "Mechanism of Action - Tactical Therapeutics", (2013-10-19), URL: http://www.tacticaltherapeutics.com/mechanism-action/, (2017-01-24) *
Geoffrey Shapiro ET AL, "A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer", (2013-06-02), URL: http://www.medsci.cn/webeditor/uploadfile/201306/2013-06-02210743756.pdf, (2017-01-24) *

Also Published As

Publication number Publication date
KR20160030535A (ko) 2016-03-18
WO2015017545A1 (en) 2015-02-05
KR102389934B1 (ko) 2022-04-21
JP6913459B2 (ja) 2021-08-04
CN105531380A (zh) 2016-04-27
US20150038349A1 (en) 2015-02-05
US10378059B2 (en) 2019-08-13
AU2014296212A1 (en) 2016-02-25
EP3027776C0 (en) 2024-02-07
EP3027776B1 (en) 2024-02-07
IL243894B (en) 2020-06-30
CA2919690A1 (en) 2015-02-05
JP2016526908A (ja) 2016-09-08
IL243894A0 (en) 2016-04-21
CA2919690C (en) 2021-11-02
EP3027776A4 (en) 2017-03-08
HK1220493A1 (en) 2017-05-05
EP3027776A1 (en) 2016-06-08
CN105531380B (zh) 2021-07-13

Similar Documents

Publication Publication Date Title
Greco et al. DNA hydroxymethylation controls cardiomyocyte gene expression in development and hypertrophy
Jin et al. Androgen receptor genomic regulation
Wang et al. ArhGAP30 promotes p53 acetylation and function in colorectal cancer
GB2615975A (en) Methods and systems for determining a pregnancy-related state of a subject
Lee et al. HBx induces hypomethylation of distal intragenic CpG islands required for active expression of developmental regulators
Chen et al. Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples
Garitano-Trojaola et al. Long non-coding RNAs in haematological malignancies
Yang et al. Immune-related genes in tumor-specific CD4+ and CD8+ T cells in colon cancer
Zhang et al. Identification of the key transcription factors in esophageal squamous cell carcinoma
Zang et al. Differential expression profiling of microRNAs and their potential involvement in esophageal squamous cell carcinoma
Herrer et al. Gene expression network analysis reveals new transcriptional regulators as novel factors in human ischemic cardiomyopathy
AU2014296212B2 (en) Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
Han et al. Dynamic DNA 5-hydroxylmethylcytosine and RNA 5-methycytosine reprogramming during early human development
Choi et al. Epigenetic landscape change analysis during human EMT sheds light on a key EMT mediator TRIM29
Saleh et al. The long non-coding RNAs (lncRNA) in the pathogenesis of gastric cancer cells: molecular mechanisms and involvement miRNAs
CN110093422A (zh) Linc02159在肺腺癌诊疗中的应用
Prensner et al. Transcriptome sequencing identifies PCAT-1, a novel lincRNA implicated in prostate cancer progression
Sadasivam et al. The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
Nandagopal et al. Long non coding RNA in triple negative breast cancer: a promising biomarker in tumorigenesis
Cserhati et al. Motifome comparison between modern human, Neanderthal and Denisovan
Wu et al. Exosome and lipid metabolism-related genes in pancreatic adenocarcinoma: a prognosis analysis
Brovkina et al. Identification of novel differentially expressing long non-coding RNAs with oncogenic potential
Kumar et al. Comparative RNA-seq analysis reveals dys-regulation of major canonical pathways in ERG-inducible LNCaP cell progression model of prostate cancer
Liang et al. Identification of novel hub genes and lncRNAs related to the prognosis and progression of pancreatic cancer by microarray and integrated bioinformatics analysis
Court et al. Modulated contact frequencies at gene-rich loci support a statistical helix model for mammalian chromatin organization

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)